| Ticker |
CPRX
|
| CIK | 0001369568 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL, 33134 |
| Website | catalystpharma.com |
| Phone | (305) 529-2522 |
| CEO | Patrick J. McEnany |
| Employees | 80 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy NowWe recently published a list of 11 Stocks with Consistent Growth to Buy Now. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against stocks with consistent growth to buy now. The market is clouded by friction between trading partners. But even at these uncertain times, one […] Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednes Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts?We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against other best Russell 2000 stocks to buy according to Wall Street analysts. Since President Trump announced new tariffs, the […] Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% DipCatalyst Pharmaceuticals (NasdaqCM:CPRX) saw a minor decline of 3% over the past month amidst a backdrop of broader market volatility triggered by new tariffs and economic uncertainties. Despite the relatively modest price movement for the company compared to the significant 12% market drop, potential concerns related to ongoing tariff discussions in the pharmaceutical sector may have added weight. As broader economic concerns and tariff-related market downturns continue to influence investor... |
